Overview

Nintedanib is a small-molecule angiotargeted inhibitor that simultaneously blocks multiple receptor tyrosine kinases involved in angiogenesis and fibroblast activation, including VEGFR1–3, FGFR1–3, and PDGFRα/β. By interfering with the pro-angiogenic and profibrotic signaling that supports both tumor vasculature and lung scar tissue, it addresses two disease mechanisms with one molecule. The 100 mg soft capsule format is a practical, temperature-stable SKU for distributors serving oncology and pulmonary programs, and it reduces warehouse complexity compared with refrigerated biologics. Unlike intravenous anti-angiogenic monoclonal antibodies, the oral capsule avoids infusion-suite capacity and fits ambulatory care pathways in markets with varied healthcare infrastructure.

How It Works

Nintedanib competes with ATP at the intracellular kinase domain of its targets, dampening the downstream signaling that drives new blood-vessel formation and fibroblast proliferation. In non-small cell lung cancer this anti-angiogenic action complements cytotoxic chemotherapy by normalizing the tumor vasculature and limiting nutrient delivery. In idiopathic pulmonary fibrosis, the same kinase blockade reduces fibroblast migration and differentiation, slowing forced vital capacity decline and the progressive scarring that defines the disease. By lowering vascular endothelial growth factor signaling, it also reduces the leaky microvasculature that contributes to malignant effusion and tissue edema in advanced disease.

Indications

Nintedanib is used in locally advanced, metastatic, or recurrent non-small cell lung cancer of adenocarcinoma histology, often combined with docetaxel after prior chemotherapy. It is also approved for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease, where it slows functional deterioration. The shared mechanism across cancer and fibrosis makes it unusual among targeted agents and attractive to distributors covering both therapy areas from one catalogue line. In several regions it is additionally studied as maintenance after first-line chemotherapy, extending its relevance to partners planning repeat-order demand across continuing programs.

Dosage & Administration

The typical regimen is 150 mg twice daily with food; the 100 mg strength supports dose adjustment or initiation in sensitive patients. Capsules are taken at mealtimes to improve gastrointestinal tolerability, and interruptions follow managing hepatic and bowel signals.

Storage & Sourcing

Soft capsules are packed in moisture-protective blisters with desiccant, stable under standard cold-chain conditions. GIVE LIFE TIME International provides batch certificates and compliant export paperwork for international buyers.

FAQ

Q: Which pathways does nintedanib block? A: It inhibits VEGFR, FGFR, and PDGFR families, addressing both tumor angiogenesis and pulmonary fibrosis signaling.

Q: Why is it used in lung cancer and IPF? A: The same kinase network drives abnormal vessel growth in cancer and scar formation in IPF, so one inhibitor serves both indications.

Q: How is the 100 mg strength used? A: It supports dose reduction or gentle initiation when tolerability requires a lower exposure than the standard 150 mg dose.